

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Disease models			
Human cellular model of serous ovarian carcinoma	A cellular model of serous ovarian carcinoma could help identify markers and therapeutic targets of the disease. In a fallopian epithelial cell line derived from healthy subjects, expression of <i>c-Myc</i> and knockdown of a <i>protein phosphatase 2 (PPP2CA; PP2A)</i> subunit resulted in greater rates of growth, proliferation and colony formation than those in the unmodified cell line. Injection of the modified cells in normal mice produced tumors that expressed markers associated with serous ovarian carcinoma. Ongoing work includes using the model to identify genetic factors involved in disease development and progression as potential therapeutic targets and/or markers for early detection.	Patented by the Dana-Farber Cancer Institute; available for licensing	Karst, A. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online April 18, 2011; doi:10.1073/pnas.1017300108 Contact: Ronny Drapkin, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Mass. e-mail: ronny_drapkin@dfci.harvard.edu
	<i>SciBX</i> 4(16); doi:10.1038/scibx.2011.464 Published online April 21, 2011		